A Phase 1 interventional study of 18F-AV-1451 and PET in Primary Progressive Aphasia With Suspected Alzheimer's Disease, sponsored by University of Chicago. Completed at 1 site in United States. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-04-06.
Sponsored by University of Chicago · Phase 1, Interventional, and Diagnostic
Among 1,937 studies in Alzheimer Disease with a site in United States — 343 open to participants now, 444 under way, 39 of them phase 3. Alzheimer Disease · United States.
Among the 1,937 studies in Alzheimer Disease with a site in United States, this one is the 817th largest by planned enrollment of the 1,606 interventional ones, is one of 87 that started in 2016, is one of 304 in phase 1, and was the 780th registered.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's planned enrollment of 70 is close to the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →343 of the 1,937 studies in Alzheimer Disease with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 641 Alzheimer Disease studies recruiting now, 283 (44%) set no upper age limit and 54 (8%) stop at 75 or younger; 34 take children under 18; 283 take healthy volunteers.
This study: 20 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →1,937 studies; the count open now beside each. This study's row is marked.
First in 1981; this study’s year is marked. 87 started in 2016.
Median enrollment 73 across the 1,606 interventional studies, 160 across the 309 observational. Of the 1,376 that completed or were terminated, 590 (43%) have results posted.
730 of 1,937 have an industry lead sponsor. The 10 most frequent:
University of Chicago is the lead sponsor of 924 studies on the registry; 185 are open to participants now.
Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.
University of Chicago has 8 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
165 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Among the 1,937 studies in Alzheimer Disease with a site in United States, from their registry updates:
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
Drug: 18F-AV-1451 · Device: PET
Also known as: AV-1451
PET scanner for brain imaging
Tau levels in PPA participants
Tau deposition as measured by 18F-AV-1451 standardized uptake value ratio (SUVR) in cortical and medial temporal regions.
Time frame: 2 years
The record gives a start of Feb 2016, a primary completion of Feb 2025 and a completion of Feb 2025. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.